50 participants
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-02
- Start Date:
- 2023-03-06
- Completion:
- 2027-07-22
Conditions
- Graft vs Host Disease
Interventions
- DRUG
No Results Yet